ANNUAL REPORT 2021
LUNDBECK
ANNUAL REPORT 2021
= CONTENTS
IQVIA
**
In 2020, NortheraⓇ was included in strategic brands and revenue from strategic
brands was therefore DKK 7,845 million.
18/111
NORTH AMERICA
Revenue reached DKK 8,245 million in 2021 compared to DKK
9,790 million in 2020. Sales were impacted by generic erosion
of mature neurology products, especially NortheraⓇ as well as
depreciation of currencies. Excluding NortheraⓇ, sales increased
by 4.7% reported. The COVID-19 pandemic continues to impact
business in the region and especially TrintellixⓇ since that
product relies heavily on switches and new-to-brand
prescriptions which are significantly less likely in telehealth
visits. The strategic brands increased by 18% in local currencies
and reached DKK 6,022 million or 73% of sales. North America
constituted 52% of total revenue (excluding effects from hedging
and Other revenue), which is a small decrease from last year.
Abilify MaintenaⓇ revenue reached DKK 1,019 million,
representing Lundbeck's share of total net sales. In the U.S.,
Abilify MaintenaⓇ has a stable volume market share of around
21% and in Canada it reached 32.7% by October 2021
representing a slight increase from January 2021*.
TrintellixⓇ sales reached DKK 1,789 million in revenue for
Lundbeck representing a growth in local currencies of 9%. The
volume market share in the U.S. is unchanged at 0.9% by
October 2021. In Canada, the volume share has increased from
1.4% of the total anti-depressant market in January to 1.7% in
October 2021. The value market share of the total anti-
depressant market in the U.S. has increased from 24.2% to
26.7%. In Canada, the value market share of the total anti-
depressant market has increased from 7.7% in January 2021 to
10.1% in October*.
Lundbeck's share of RexultiⓇ revenue reached DKK 2,725
million with a growth of 12% in local currencies. In the U.S.,
RexultiⓇ has a volume market share of 2.2% by October 2021
which is unchanged from January 2021*. However, the value
share has increased from 14.6% to 15.5%. In Canada, the
product has reached volume share of 3.1% representing a slight
increase. Patient data suggest that more than 3/4 of
prescriptions in the U.S. are prescribed for MDD.
VyeptiⓇ was approved by the FDA on 21 February 2020 and in
Canada in January 2021 for the preventive treatment of
migraine in adults. The product was made available in the U.S.
on 6 April 2020 and reached sales of DKK 489 million in 2021 in
line with expectations. VyeptiⓇ can be obtained via selected
specialty distributors and specialty pharmacies. Around 110
million insured U.S. individuals have access to VyeptiⓇ without
any branded step-edits. In total, more than 235 million
individuals have access to VyeptiⓇ. We expect to launch in
Canada in 2022. It is still early in the launch, and the uptake has
been affected by the general decline in physician-administered
medicines during the pandemic. Nonetheless, we see
increasing numbers of patients being treated with VyeptiⓇ, and
we are encouraged by the positive feedback from clinicians and
patients, who have used the product, on the positive effects and
the ease of use. Based on the current momentum and the
positive feedback, we expect continued strong growth for the
product.
NortheraⓇ sales reached DKK 665 million for the year following
the launch of several generic versions in February 2021. SabrilⓇ
revenue reached DKK 657 million. OnfiⓇ revenue reached DKK
505 million.
REVENUE - NORTH AMERICA
VyeptiⓇ
Growth
in local
DKKm
2021
2020
Growth
currencies
Abilify MaintenaⓇ
Trintellix®
1,019
980
4%
7%
1,789 1,682
6%
9%
RexultiⓇ
Strategic brands
NortheraⓇ
2,725 2,537
489
6,022 5,292**
7%
12%
93
426%
443%
14%
18%
665 2,553
(74%) (72%)
OnfiⓇ
SabrilⓇ
505
642 (21%)
(17%)
657
777 (15%) (11%)
Other pharmaceuticals
Total revenue
396 526 (25%)
8,245 9,790 (16%)
(24%)
(12%)View entire presentation